亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial

医学 心力衰竭 耐受性 指南 随机对照试验 内科学 打开标签 重症监护医学 不利影响 病理
作者
Alexandre Mebazaa,Beth A. Davison,Ovidiu Dragomir Chioncel,Alain Cohen Solal,Rafael Díaz,Gerasimos S Filippatos,Marco Metra,Piotr P. Ponikowski,Karen S Sliwa,Adriaan A. Voors,Christopher Edwards,Maria Novosadova,Koji Takagi,Albertino Damasceno,Hadiza Saidu,Étienne Gayat,Peter S. Pang,Jelena Čelutkienė,Gad Cotter
出处
期刊:The Lancet [Elsevier BV]
卷期号:400 (10367): 1938-1952 被引量:1284
标识
DOI:10.1016/s0140-6736(22)02076-1
摘要

Background There is a paucity of evidence for dose and pace of up-titration of guideline-directed medical therapies after admission to hospital for acute heart failure. Methods In this multinational, open-label, randomised, parallel-group trial (STRONG-HF), patients aged 18–85 years admitted to hospital with acute heart failure, not treated with full doses of guideline-directed drug treatment, were recruited from 87 hospitals in 14 countries. Before discharge, eligible patients were randomly assigned (1:1), stratified by left ventricular ejection fraction (≤40% vs >40%) and country, with blocks of size 30 within strata and randomly ordered sub-blocks of 2, 4, and 6, to either usual care or high-intensity care. Usual care followed usual local practice, and high-intensity care involved the up-titration of treatments to 100% of recommended doses within 2 weeks of discharge and four scheduled outpatient visits over the 2 months after discharge that closely monitored clinical status, laboratory values, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations. The primary endpoint was 180-day readmission to hospital due to heart failure or all-cause death. Efficacy and safety were assessed in the intention-to-treat (ITT) population (ie, all patients validly randomly assigned to treatment). The primary endpoint was assessed in all patients enrolled at hospitals that followed up patients to day 180. Because of a protocol amendment to the primary endpoint, the results of patients enrolled on or before this amendment were down-weighted. This study is registered with ClinicalTrials.gov, NCT03412201, and is now complete. Findings Between May 10, 2018, and Sept 23, 2022, 1641 patients were screened and 1078 were successfully randomly assigned to high-intensity care (n=542) or usual care (n=536; ITT population). Mean age was 63·0 years (SD 13·6), 416 (39%) of 1078 patients were female, 662 (61%) were male, 832 (77%) were White or Caucasian, 230 (21%) were Black, 12 (1%) were other races, one (<1%) was Native American, and one (<1%) was Pacific Islander (two [<1%] had missing data on race). The study was stopped early per the data and safety monitoring board's recommendation because of greater than expected between-group differences. As of data cutoff (Oct 13, 2022), by day 90, a higher proportion of patients in the high-intensity care group had been up-titrated to full doses of prescribed drugs (renin-angiotensin blockers 278 [55%] of 505 vs 11 [2%] of 497; β blockers 249 [49%] vs 20 [4%]; and mineralocorticoid receptor antagonists 423 [84%] vs 231 [46%]). By day 90, blood pressure, pulse, New York Heart Association class, bodyweight, and NT-proBNP concentration had decreased more in the high-intensity care group than in the usual care group. Heart failure readmission or all-cause death up to day 180 occurred in 74 (15·2% down-weighted adjusted Kaplan-Meier estimate) of 506 patients in the high-intensity care group and 109 (23·3%) of 502 patients in the usual care group (adjusted risk difference 8·1% [95% CI 2·9–13·2]; p=0·0021; risk ratio 0·66 [95% CI 0·50–0·86]). More adverse events by 90 days occurred in the high-intensity care group (223 [41%] of 542) than in the usual care group (158 [29%] of 536) but similar incidences of serious adverse events (88 [16%] vs 92 [17%]) and fatal adverse events (25 [5%] vs 32 [6%]) were reported in each group. Interpretation An intensive treatment strategy of rapid up-titration of guideline-directed medication and close follow-up after an acute heart failure admission was readily accepted by patients because it reduced symptoms, improved quality of life, and reduced the risk of 180-day all-cause death or heart failure readmission compared with usual care. Funding Roche Diagnostics.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yc发布了新的文献求助10
1秒前
梓亮完成签到,获得积分10
1秒前
无限白安完成签到,获得积分10
3秒前
9秒前
13秒前
缓慢的秋荷完成签到,获得积分10
26秒前
打打的应助被whc采纳,获得10
36秒前
42秒前
whc发布了新的文献求助10
48秒前
泠漓完成签到 ,获得积分10
50秒前
GraceHill492发布了新的文献求助40
59秒前
1分钟前
开放的乐驹完成签到 ,获得积分10
1分钟前
科研通AI6.3的应助被雪白书蝶采纳,获得10
1分钟前
1分钟前
失眠的白云完成签到,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
星辰大海的应助被荷兰香猪采纳,获得10
2分钟前
2分钟前
2分钟前
雪白书蝶发布了新的文献求助10
2分钟前
荷兰香猪发布了新的文献求助10
2分钟前
2分钟前
2分钟前
雪白书蝶完成签到,获得积分10
2分钟前
Moto_Fang完成签到 ,获得积分10
2分钟前
3分钟前
3分钟前
KaK完成签到,获得积分10
3分钟前
Lemenchichi完成签到,获得积分10
3分钟前
今后的应助被荷兰香猪采纳,获得10
3分钟前
3分钟前
木槿花有枝芽完成签到 ,获得积分10
3分钟前
荷兰香猪发布了新的文献求助10
3分钟前
3分钟前
3分钟前
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190159
求助须知:如何正确求助?哪些是违规求助? 9577257
关于积分的说明 21852297
捐赠科研通 7788567
什么是DOI,文献DOI怎么找? 3436279
关于科研通互助平台的介绍 2560058
邀请新用户注册赠送积分活动 2482880